Skip to main content
. 2022 Apr 19;54(4):455–465. doi: 10.1038/s12276-022-00757-5

Fig. 3. Antisense oligonucleotide-based RNA drugs.

Fig. 3

a Primary mechanism of action for antisense oligonucleotide (ASO)-based RNA drugs in human cells. ASOs can modulate splicing or induce RNase H-mediated degradation of the target mRNA. b Mipomersen, a drug used in the treatment of homozygous familial hypercholesterolemia, induces the degradation of apolipoprotein B-100 (ApoB-100) mRNA. c Nusinersen binds to the intronic splicing silencer element in the intron of survival motor neuron 2 (SMN2) pre-mRNA, which blocks the exon 7 skipping associated with SMN type diseases. Consequently, SMN2 mRNA is spliced like SMN1 mRNA, resulting in the production of stable SMN proteins. d In some patients with Duchenne muscular dystrophy, a mutation at exon 51 of dystrophin (DMD) mRNA induces premature termination of translation, preventing the production of functional protein. Eteplirsen binds to the exonic splicing enhancer in this exon and induces exon 51 skipping. This results in the production of smaller amounts of fully functional proteins.